📊 CYAND Key Takeaways
Investment Thesis
Cyanotech exhibits deteriorating financial health with persistent operating losses, negative free cash flow, and weak liquidity despite modest revenue growth. The company is burning cash while struggling to maintain profitability, indicating fundamental operational challenges in its medicinal chemicals and botanical products business.
CYAND Strengths
- Positive revenue growth of 5.0% YoY shows market demand persistence
- Reasonable gross margin of 32.6% indicates production efficiency at unit level
- Moderate leverage with debt-to-equity ratio of 0.52x provides some financial flexibility
CYAND Risks
- Negative operating cash flow of -220K and free cash flow of -306K indicate unsustainable burn rate
- Critical liquidity concerns with current ratio of 1.00x and quick ratio of 0.30x; cash position of only 649K insufficient for ongoing operations
- Persistent net losses (-925K) and negative interest coverage of -1.6x suggest inability to service debt from operations
- Operating margin of -4.4% indicates core business is unprofitable despite gross margin strength, suggesting overhead burden and operational inefficiency
Key Metrics to Watch
- Operating cash flow trend - must turn positive to ensure viability
- Cash balance and runway - critical given current burn rate
- Operating margin improvement - path to profitability at EBITDA level
- Revenue growth sustainability - whether 5% growth can accelerate
CYAND Financial Metrics
💡 AI Analyst Insight
CYANOTECH CORP presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
CYAND Profitability Ratios
CYAND vs Default Sector
How CYANOTECH CORP compares to Default sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CYAND Balance Sheet & Liquidity
CYAND 5-Year Financial Trend
5-Year Trend Summary: CYANOTECH CORP's revenue has declined by 25% over the 5-year period, indicating business contraction. The most recent EPS of $0.35 reflects profitable operations.
CYAND Growth Metrics (YoY)
CYAND Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2025 | $5.8M | $1.0K | $0.00 |
| Q1 2025 | $5.8M | -$926.0K | N/A |
| Q3 2024 | $5.6M | -$224.0K | N/A |
| Q2 2024 | $5.8M | -$797.0K | $-0.13 |
| Q1 2024 | $5.1M | -$1.2M | $-0.17 |
| Q3 2023 | $5.6M | $386.0K | $0.06 |
| Q2 2023 | $5.2M | -$797.0K | $-0.13 |
| Q1 2023 | $5.1M | -$472.0K | $-0.08 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CYAND Capital Allocation
CYAND SEC Filings
Access official SEC EDGAR filings for CYANOTECH CORP (CIK: 0000768408)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CYAND
What is the AI rating for CYAND?
CYANOTECH CORP (CYAND) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CYAND's key strengths?
Positive revenue growth of 5.0% YoY shows market demand persistence. Reasonable gross margin of 32.6% indicates production efficiency at unit level.
What are the risks of investing in CYAND?
Negative operating cash flow of -220K and free cash flow of -306K indicate unsustainable burn rate. Critical liquidity concerns with current ratio of 1.00x and quick ratio of 0.30x; cash position of only 649K insufficient for ongoing operations.
What is CYAND's revenue and growth?
CYANOTECH CORP reported revenue of $12.8M.
Does CYAND pay dividends?
CYANOTECH CORP does not currently pay dividends.
Where can I find CYAND SEC filings?
Official SEC filings for CYANOTECH CORP (CIK: 0000768408) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CYAND's EPS?
CYANOTECH CORP has a diluted EPS of $-0.13.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.